Language selection

Government of Canada / Gouvernement du Canada

Search

Cost-effectiveness of palivizumab prophylaxis for respiratory syncytial virus (RSV) : a systematic review.: HP40-320/2022E-PDF

"Palivizumab (PVZ) prophylaxis is used as passive immunization for respiratory syncytial virus (RSV). However, due to its high acquisition costs, the value of this intervention is unclear. The objective of this study was to systematically review the cost-effectiveness of PVZ prophylaxis compared to no prophylaxis in infants under 24 months of age"--Executive summary, page 3.

Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.914232&sl=0

Publication information
Department/Agency
  • Public Health Agency of Canada, issuing body.
TitleCost-effectiveness of palivizumab prophylaxis for respiratory syncytial virus (RSV) : a systematic review.
Publication typeMonograph
Language[English]
Other language editions[French]
FormatDigital text
Electronic document
Note(s)
  • Cover title.
  • "Publication date: January 2023."
  • At head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI).
  • Issued also in French under title: Rapport coût-efficacité de la prophylaxie par palivizumab pour le virus respiratoire syncytial (VRS) : un examen systématique.
  • Includes bibliographical references (pages 15-18).
Publishing information
  • [Ottawa] : Public Health Agency of Canada = Agence de la santé publique du Canada, 2023.
  • ©2023
Description1 online resource (41 pages) : graphs
ISBN9780660449364
Catalogue number
  • HP40-320/2022E-PDF
Departmental catalogue number220361
Subject terms
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.

Page details

Report a problem or mistake on this page
Date modified: